Pictilisib (GDC-0941)

Catalog No.S1065 Synonyms: RG7321

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Cited by 76 Publications

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )
Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )
P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	MY\LbY5ie2ViQYPzZZk>		NIPXXHoyKGh?	M4LKOWROW09?	MWfJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGSnbIThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1?	NIrQeIIyQDd3NE[1OC=>
Sf9	NX\EcmF{U2mwYYPlJGF{e2G7		MX[xJIg>	M{j1ZmROW09?	MVfJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGgTFExPDdvUjDteZRidnRiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bkd2W6cILld5NqdmdicEi1ZYxxcGFid3n0bEBKSzVyIH;mJFAvODB\|IN88US=>	M4\xc\|E5PzV2NkW0
Sf9	NX74fZN1U2mwYYPlJGF{e2G7		Mnj6NUBp	M2OyTGROW09?	Mn3oTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGU2PDVvSzDteZRidnRiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bkd2W6cILld5NqdmdicEi1ZYxxcGFid3n0bEBKSzVyIH;mJFAvODB\|IN88US=>	M1TRU\|E5PzV2NkW0
Sf9	NIi4fpBMcW6jc3WgRZN{[Xl?		Ml;VNUBp	MkfrSG1UVw>?	MWrJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMEOzJO69VQ>?	M2jGOlE5PzV2NkW0
Sf9	NHvve5VMcW6jc3WgRZN{[Xl?		M361XlEhcA>?	NGTEW4JFVVOR	NXvTS2N7UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDhcJBp[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJINw\XiycnXzd4lv\yCyOEXhcJBp[Q>?	MXWxPFc2PDZ3NB?=
MDA-MB-361	NF;qWo9HfW6ldHnvckBCe3OjeR?=		MofzNkBp	MXHEUXNQ	M4THdGlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvODJ6IN88US=>	MlPONVg4PTR4NUS=
PC3	MmrQSpVv[3Srb36gRZN{[Xl?		NF\PcVMzKGh?	MnnFSG1UVw>?	MofWTY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdiCrbjDQWGVPNW63bHygbJVu[W5iUFOzJINmdGy\|IIfpeIghUUN3MDDv[kAxNjB\|NzFOwG0>	NHi1PFQyQDd3NE[1OC=>
U87MG	MnHSSpVv[3Srb36gRZN{[Xl?		NFXmco0zKGh?	M{jnUWROW09?	NEDZbJFKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wOFYh\|ryP	NYe2SopJOTh5NUS2OVQ>
MDA-MB-361	MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{HmXVk3KGh?	NIjJVXhFVVOR	NYjvSG1nSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvM{[xJINmdGy\|IIfpeIghWEmNM1PBJGU2PDVvSzDteZRifGmxbjD3bZRpKEmFNUCgc4YhOC55MjFOwG0>	MXuxPFc2PDZ3NB?=
A2780	M1W2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUXhT3ZMQTZiaB?=	NHW5UXdFVVOR	NYTzPXRVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIGDJT\|NESSCjbnSgVHRGViCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4yPCEQvF2=	NYrCeZJROTh5NUS2OVQ>
PC3	M{LyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mmi3PVYhcA>?	MkDmSG1UVw>?	NEPyWVFKSzVyPUCuNlgh\|ryP	MY[xPFc2PDZ3NB?=
U87MG	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHzXb286PiCq	NHPPNFFFVVOR	M1LUeWlEPTB;MD65OUDPxE1?	MlvVNVg4PTR4NUS=
Sf9	Mnf6T4lv[XOnIFHzd4F6		NH65eY4{OCCvaX6=	MUnEUXNQ	M1e3SGlvcGmkaYTpc44hd2ZiaIXtZY4hWEl\|S3fhcY1iKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDhcY92dnRib3[gRXRRKGOxboP1cYVlKHerdHigTWM2OCCxZjCwMlA1OiEQvF2=	NG\rVFczOjV2OEO0Ni=>
RAW 264.7	M{TrU2tqdmG\|ZTDBd5NigQ>?		MVu5NEBucW5?	MUXEUXNQ	NUHjVVBvUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPL[4FudWFiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUig{txO	MYKyNlU1QDN2Mh?=
Sf9	MVXLbY5ie2ViQYPzZZk>		NV3QbohrOSCq		MkLYTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4JmfGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOIOTDj[YxteyC5aYToJGlEPTBib3[gNE4xOTdizszN	NWrVXIRHOjN3NEC2OFU>
Sf9	NX3WPHp3U2mwYYPlJGF{e2G7		MmD5NUBp		M3yzfGlvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2tl\Wy2YTDlfJBz\XO\|ZXS=	M1fTWFI{PTRyNkS1
Sf9	MmGyT4lv[XOnIFHzd4F6		MYOxJIg>		NIHGbG5KdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM\2GvbXGg[ZhxemW\|c3Xk	NVvZeJU6OjN3NEC2OFU>
Sf9	MY\LbY5ie2ViQYPzZZk>		MkTLNUBp		NWizbmVZUW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2GucHjhJIV5eHKnc4Pl[C=>	NGrx[ZEzOzV2ME[0OS=>
SKOV3	M3n4XWtqdmG\|ZTDBd5NigQ>?	M2nu[VEh\|ryP	MXqxJIg>	NHzG[YZFVVOR	MnnzTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdg>?	MUSyN\|M3ODN2OB?=
MCF7	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1r6bFEh\|ryP	NGnBO\|k6PiCq	NXvOV4lmTE2VTx?=	NHLKR4xIUTVyPUCuNFcxOiEQvF2=	MlrGNlM{PjB\|NEi=
SKOV3	NE\5UmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\He\|g{OSEQvF2=	NVSxdYxSQTZiaB?=	Ml7rSG1UVw>?	MoC2S2k2OD1yLkG0O\|Yh\|ryP	NHu0cmMzOzN4MEO0PC=>
PC3	NFW4RWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{PGWVczKGh?	M3TGU2ROW09?	NXnSZ\|dGUUN3ME2wMlI5KM7:TR?=	MUKyNVk5OTdzNB?=
MCF7.1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGLGXWg4OiCq	MWDEUXNQ	NFTscpRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKEiHUkKg[4Vv\SC5aYToJGlEPTBib3[gNE4zQCEQvF2=	NHLvNFczOTl6MUexOC=>
MCF7-neo/Her2	MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mme5O\|IhcA>?	M1rpNGROW09?	NUe2XHRWUUN3ME2wMlI6KM7:TR?=	NVnZU2IyOjN4NkK5NFM>
MCF7-neo/Her2	NX6zNmtpU2mwYYPlJGF{e2G7				NV\XPGVkUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIFHLWEBxcG:\|cHjvdplt[XSrb36gZZQhWzR5MzD3bZRpKEmFNUCgc4YhOC5yMEeg{txO	Mo\rNlM3PjJ7MEO=
PC3	M3HMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnO5O\|IhcA>?	NYfKXJhoTE2VTx?=	MXrFR\|UxRTBwM{Sg{txO	NHX0cIEzOTl6NU[zPS=>
MCF7.1	NFL5RVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHy4cpE4OiCq	NYjwPIt[TE2VTx?=	MmTuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiRVO1NEBw\iByLkO5JO69VQ>?	NV\uVlRVOjF7OEW2N\|k>
PC3	NWm4SFM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1jOSFczKGh?	M{nKU2ROW09?	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCmZX\pZ4lmdnRiaX6gVHRGViC5aYToJGlEPTBib3[gNE4{QSEQvF2=	M{fPPVIxODVyNk[5
MCF7.1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mke0O\|IhcA>?	MUnEUXNQ	M1zYXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochWEl\|S3HsdIhiKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6zOEDPxE1?	MoXSNlAxPTB4Nkm=
MCF7.1	NUO1fpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MonYO\|IhcA>?		M3HkZWVEPTB;MD63NkDPxE1?	M2fKUFIxOzR4NkW2
NCI-H1975	NVXZRpQzS3m2b4TvfIlkKEG\|c3H5		M{fVVFczKGh?		MVXJR\|UxRTBwMkeg{txO	NEnIXIkzOzB3OUW0OS=>
H460	NGq4eVJEgXSxdH;4bYMhSXO\|YYm=		MknWO\|IhcA>?		Mn;nTWM2OD1yLki3JO69VQ>?	MlrhNlMxPTl3NEW=
HT-29	NIHSUXdEgXSxdH;4bYMhSXO\|YYm=		NWLJcFQ{PzJiaB?=		NF\reXdKSzVyPUCuOlYh\|ryP	MUWyN\|A2QTV2NR?=
HepG2	MojRR5l1d3SxeHnjJGF{e2G7		MWC3NkBp		M2HKPWlEPTB;MTFOwG0>	NIOwe\|kzOzB3OUW0OS=>
SGC7901	NE\QelFEgXSxdH;4bYMhSXO\|YYm=		MVy3NkBp		M3zDPWlEPTB;MT64JO69VQ>?	M3nPS\|I{ODV7NUS1
NCI-H226	NFTVZY9EgXSxdH;4bYMhSXO\|YYm=		NWHSRnA5PzJiaB?=		MVPJR\|UxRTJwOTFOwG0>	NUXsfVBjOjNyNUm1OFU>
A549	MoDRR5l1d3SxeHnjJGF{e2G7		NVXIc4xMPzJiaB?=		NHXmN5VKSzVyPU[uPUDPxE1?	NET1UVgzOzB3OUW0OS=>
U87MG	M2PhbmN6fG:2b4jpZ{BCe3OjeR?=		M2\oeVczKGh?		MU\JR\|UxRTdwN{eg{txO	MkXPNlMxPTl3NEW=
HBC4	NHXROZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjRZm1td2eJSUWwQU03NjB\|IF2=	MVWyNlM{PjJ2Nh?=
BSY1	MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF74OJRtd2eJSUWwQU03NjlyIF2=	M2\WflIzOzN4MkS2
HBC5	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7UcI9oT0l3ME2tOk43OCCP	Mn;WNlI{OzZ{NE[=
MCF7	NWnSRYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjsc4dIUTVyPT23MlM{KE1?	NYCzXFN7OjJ\|M{[yOFY>
MDA-MB-231	M3S4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnsc4dIUTVyPT21MlQ3KE1?	NHfSbFYzOjN\|NkK0Oi=>
U251	NGHxTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfMdmJtd2eJSUWwQU02NjVyIF2=	NEDqVZQzOjN\|NkK0Oi=>
SF268	M17oTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPsc4dIUTVyPT21MlM6KE1?	NUX1NXhHOjJ\|M{[yOFY>
SF295	M4fvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHj4eFdtd2eJSUWwQU03NjN5IF2=	NIGxbGszOjN\|NkK0Oi=>
SF539	NH7lcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;YSoxw\0eLNUC9MVYvPTBiTR?=	NVHMR3B[OjJ\|M{[yOFY>
SNB75	NH31XIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnsc4dIUTVyPT23MlExKE1?	NEi2WowzOjN\|NkK0Oi=>
SNB78	M{W2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIm3N2ttd2eJSUWwQU03NjV{IF2=	M{n5ZlIzOzN4MkS2
HCC2998	NWG5codsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUK2UoZydG:pR1m1NF0uPi5{OTDN	MkTiNlI{OzZ{NE[=
KM12	MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPsc4dIUTVyPT21Mlc3KE1?	MYKyNlM{PjJ2Nh?=
HT-29	NXnw[297T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rKSIxw\0eLNUC9MVYvOzBiTR?=	MVmyNlM{PjJ2Nh?=
HCT15	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfhcI9oT0l3ME2tOk4yOiCP	M1PiXlIzOzN4MkS2
HCT116	NHXtVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrHSppjdG:pR1m1NF0uPS56NzDN	Mm\hNlI{OzZ{NE[=
NCI-H23	NIToeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4P5c4xw\0eLNUC9MVUvPzNiTR?=	MYiyNlM{PjJ2Nh?=
NCI-H226	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1yy[oxw\0eLNUC9MVYvOjFiTR?=	NUOxeWJuOjJ\|M{[yOFY>
NCI-H522	M2fx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEj2dlJtd2eJSUWwQU03NjV6IF2=	MUWyNlM{PjJ2Nh?=
NCI-H483	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3uV2l7dG:pR1m1NF0uPi53NjDN	MUGyNlM{PjJ2Nh?=
A549	NH:1WGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3LcI9oT0l3ME2tOk4yPSCP	MnLDNlI{OzZ{NE[=
DMS273	NYTKbnFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvicI9oT0l3ME2tOk41OyCP	NI\3[48zOjN\|NkK0Oi=>
DMS114	M4\1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vXWIxw\0eLNUC9MVUvQTJiTR?=	MnLMNlI{OzZ{NE[=
LOXIMVI	MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnOb2Jtd2eJSUWwQU03NjJ7IF2=	NWTFS4pxOjJ\|M{[yOFY>
OVCAR3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HDWIxw\0eLNUC9MVYvPzFiTR?=	NFvpTmczOjN\|NkK0Oi=>
OVCAR4	M2nkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rs[Yxw\0eLNUC9MVUvPzZiTR?=	NGD2R3UzOjN\|NkK0Oi=>
OVCAR5	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjuU4Ntd2eJSUWwQU03NjJ4IF2=	MW[yNlM{PjJ2Nh?=
OVCAR8	NGPjRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXJcI9oT0l3ME2tOU44OyCP	NVzCdGlQOjJ\|M{[yOFY>
SKOV3	MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjze41ldG:pR1m1NF0uPi53MjDN	MYGyNlM{PjJ2Nh?=
RXF631L	MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHsc4dIUTVyPT22Mlg5KE1?	Mk[wNlI{OzZ{NE[=
ACHN	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDmNGNtd2eJSUWwQU03NjB5IF2=	MVGyNlM{PjJ2Nh?=
St-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moq4cI9oT0l3ME2tOU42PiCP	M4i2PVIzOzN4MkS2
MKN1	MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHiTYsxdG:pR1m1NF0uPy5yODDN	NEjWZ\|MzOjN\|NkK0Oi=>
MKN7	NGH6ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLsc4dIUTVyPT22MlUxKE1?	NGrwToIzOjN\|NkK0Oi=>
MKN28	Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUT0SYc1dG:pR1m1NF0uPS53MjDN	MYmyNlM{PjJ2Nh?=
MKN45	NYfaUFFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TiWIxw\0eLNUC9MVYvPTViTR?=	MVKyNlM{PjJ2Nh?=
MKN74	Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLPRndtd2eJSUWwQU03NjB{IF2=	M1jnSlIzOzN4MkS2
DU145	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDVNWJHdG:pR1m1NF0uPS56NTDN	NV\5[VJ[OjJ\|M{[yOFY>
PC3	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjs[XRRdG:pR1m1NF0uPi54NjDN	NVT3V\|FpOjJ\|M{[yOFY>
ES5	M3;jTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUf3UXFHUUN3ME21NE4zOSCwTR?=	NF76R5NUSU6JRWK=
HH	NHG4dWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFzMT6wPEBvVQ>?	NICz[HVUSU6JRWK=
MHH-PREB-1	M2fYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF75S5NKSzVyPUGxOE4{KG6P	M2riTXNCVkeHUh?=
NCI-H1770	M1;3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzlU5JKSzVyPUGyN{45PiCwTR?=	Ml7ZV2FPT0WU
HuO9	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfKOotnUUN3ME2yNFYvODJibl2=	M1\hb3NCVkeHUh?=
HAL-01	NXqyfFd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTJyNj63N{BvVQ>?	MXjTRW5ITVJ?
NOS-1	M3PERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTJzMT64NkBvVQ>?	NFjab5RUSU6JRWK=
HGC-27	NH:3TIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTJzMj61O{BvVQ>?	MVfTRW5ITVJ?
NB69	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDFTWM2OD1{NEWuNlchdk1?	Ml7HV2FPT0WU
RS4-11	M33ySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJ4MT63OkBvVQ>?	MlTXV2FPT0WU
DOK	M3HET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTNyMT63JI5O	M1PjeHNCVkeHUh?=
LB2241-RCC	NYnBO5ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTNyMz64OEBvVQ>?	MVHTRW5ITVJ?
NCI-H1623	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPp[G1KSzVyPUOwOE4xQCCwTR?=	M1;IdXNCVkeHUh?=
YH-13	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHL0V4dKSzVyPUOwOE4{OiCwTR?=	MV\TRW5ITVJ?
BPH-1	NXTEW4pPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfVU\|Y3UUN3ME2zNVQhdk1?	M{DxVHNCVkeHUh?=
AN3-CA	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj1XXRKSzVyPUO0NE4{PyCwTR?=	M3HWOXNCVkeHUh?=
ES7	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTN2MT65PUBvVQ>?	MYnTRW5ITVJ?
MDA-MB-175-VII	M4nxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPnTWM2OD1\|NUKuPVIhdk1?	NXLoTlRNW0GQR1XS
GAMG	MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfQWoRKSzVyPUO3NE45PSCwTR?=	MlrLV2FPT0WU
CHL-1	NGTibpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEj0RmRKSzVyPUO3PE43PSCwTR?=	MXvTRW5ITVJ?
NB7	M2fDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvYWlVKSzVyPUO4PU45OyCwTR?=	NV;TXYRuW0GQR1XS
MFE-280	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFX6e4ZKSzVyPUSxPE4zKG6P	MnXyV2FPT0WU
HL-60	NXPtb3pmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1O5UmlEPTB;NEK1Mlc2KG6P	MlzGV2FPT0WU
GCIY	NWTVUnFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3TfI5XUUN3ME20N\|MvQCCwTR?=	MV;TRW5ITVJ?
MDA-MB-361	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLSTWM2OD12M{muNVMhdk1?	M{PmfXNCVkeHUh?=
LXF-289	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\jU2lEPTB;NES4MlI4KG6P	MnX3V2FPT0WU
NBsusSR	NX\oOY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nKNWlEPTB;NEi4Mlg2KG6P	M4WyN3NCVkeHUh?=
KU-19-19	NWDkVmR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPWTWM2OD13MU[uNFchdk1?	Mo\WV2FPT0WU
A204	M1;vN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGX4e3VKSzVyPUWyNk4{OyCwTR?=	MX;TRW5ITVJ?
LB1047-RCC	NYK2Uo9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTV{Mj65N{BvVQ>?	M{fBU3NCVkeHUh?=
COLO-684	M{fzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPkXoxKSzVyPUWyN{4yOSCwTR?=	MXPTRW5ITVJ?
PA-1	NWDBbI56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\ibGhMUUN3ME21N\|IvPDFibl2=	Mo\pV2FPT0WU
MG-63	NYrWVGtMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPtTWM2OD13NEGuNVEhdk1?	NXTafndUW0GQR1XS
BHT-101	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTV2ND65OEBvVQ>?	M4HsW3NCVkeHUh?=
NKM-1	NVfscWhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGraWW9KSzVyPUW5N{4xQSCwTR?=	NUTZc2hGW0GQR1XS
T47D	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTV7Nz61OkBvVQ>?	Mlz4V2FPT0WU
MOLT-4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml35TWM2OD14MkOuOlIhdk1?	NG\XN5pUSU6JRWK=
IGROV-1	MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mom1TWM2OD14M{SuN\|Ehdk1?	MnfLV2FPT0WU
ES4	M{PtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTZ\|OT61OEBvVQ>?	MnvSV2FPT0WU
HuO-3N1	NVvmc5VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEX5PIVKSzVyPU[0Nk4{QCCwTR?=	NHTxS29USU6JRWK=
NEC8	NHThRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml36TWM2OD14NUOuOVchdk1?	MmPRV2FPT0WU
HO-1-N-1	Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTZ3OT6xO{BvVQ>?	NWTCfItYW0GQR1XS
EPCL-272H	M{\DUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXPZ5hKSzVyPU[4O{4zOSCwTR?=	M3LJb3NCVkeHUh?=
D-263MG	NIXSUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTdzOD6xJI5O	NFW5[I9USU6JRWK=
MV-4-11	M{\pZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPqTWM2OD15MkSuN\|Ehdk1?	NEW4WWdUSU6JRWK=
SK-NEP-1	NUC1e3FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTITWM2OD15MkWuPVQhdk1?	Mk\TV2FPT0WU
SW872	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTd{Nz64PUBvVQ>?	NVfkZXJtW0GQR1XS
P30-OHK	NV7qW\|VXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETWfYNKSzVyPUezNE44OSCwTR?=	NXfnTFhoW0GQR1XS
OMC-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\BNGlEPTB;N{WxMlA6KG6P	NEnzPWlUSU6JRWK=
LoVo	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTd5Nz65JI5O	MnfqV2FPT0WU
LNCaP-Clone-FGC	NIPKcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPGbotYUUN3ME23PVYvOzRibl2=	NWG4XFRZW0GQR1XS
L-363	M3vwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTd7OD60NkBvVQ>?	M2LMbnNCVkeHUh?=
ES8	M4XWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIH6WYRKSzVyPUixNE42OiCwTR?=	NI\aW2pUSU6JRWK=
697	M4PqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3W5PWlEPTB;OEOxMlU2KG6P	NV7yRXc4W0GQR1XS
HSC-3	M4rkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTh\|OT61OEBvVQ>?	NGTXd2JUSU6JRWK=
H4	M4GyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPuVJBNUUN3ME24OVAvQDVibl2=	M2LKSnNCVkeHUh?=
QIMR-WIL	M4LZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7zTWM2OD16NkWuNkBvVQ>?	MVHTRW5ITVJ?
OAW-42	NHXQfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTh5Mj6xPUBvVQ>?	MWPTRW5ITVJ?
MCF7	M37PdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPaTmxKSzVyPUi5PE42QSCwTR?=	NUD6WW9OW0GQR1XS
SCC-25	NGfOTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTlzND6xPUBvVQ>?	MWjTRW5ITVJ?
NCI-H1563	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHLTWM2OD17MUWuPVkhdk1?	M3X3fXNCVkeHUh?=
OVCAR-5	NVe1TGhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHERVhKSzVyPUm0NE4yPyCwTR?=	NIHsfYhUSU6JRWK=
HDLM-2	NUTFR29HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jydGlEPTB;OUS5MlIhdk1?	MXPTRW5ITVJ?
NB5	NGHPem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTl3Nj62JI5O	M2DwR3NCVkeHUh?=
NCI-H292	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLrTWM2OD17N{SuN\|Ihdk1?	NITHfXRUSU6JRWK=
A101D	M1izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY[ybXU{UUN3ME25PVAvOTlibl2=	MUXTRW5ITVJ?
NCI-H1648	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPjdYNtUUN3ME25PVgvPTFibl2=	MoPQV2FPT0WU
EKVX	NXLPSmhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\OcIY{UUN3ME2xMlAyOjlizszN	MnW2V2FPT0WU
SW1710	NYHNVmdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjNeGNKSzVyPUGuNFQzOzNizszN	NEPIbnhUSU6JRWK=
WM-115	NWX6O2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXGTWM2OD1zLkC2OlU3KM7:TR?=	NUHFT5JTW0GQR1XS
CAL-54	M3XWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF73b45KSzVyPUGuNFcxQDFizszN	MYfTRW5ITVJ?
TGBC24TKB	M{jOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTFwMEiwOFUh\|ryP	MnSwV2FPT0WU
NCI-H520	NYnzV2NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVew[FVjUUN3ME2xMlA5QTZ5IN88US=>	M{DWenNCVkeHUh?=
D-423MG	NV\EeZR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HPNGlEPTB;MT6wPVk3OiEQvF2=	NXvGOFNCW0GQR1XS
BFTC-905	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTFwMUO0OFkh\|ryP	M4P6XHNCVkeHUh?=
HT	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFwMUO0O\|gh\|ryP	M3ewO3NCVkeHUh?=
CTB-1	M{fURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTFwMUSyPVMh\|ryP	M4HiS3NCVkeHUh?=
Hs-578-T	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nXbGlEPTB;MT6xPVU3PSEQvF2=	NF;TWpFUSU6JRWK=
HuH-7	NVPTZVk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PKWmlEPTB;MT6yNFk1QSEQvF2=	MofHV2FPT0WU
LB996-RCC	NUPrZ3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDjPHdKSzVyPUGuNlIyPzdizszN	MlX0V2FPT0WU
KYSE-270	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPzSYpKSzVyPUGuNlk4OzRizszN	NVfKSYszW0GQR1XS
A4-Fuk	M1LnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLZTXdNUUN3ME2xMlI6QTl\|IN88US=>	MXTTRW5ITVJ?
A498	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfQTWM2OD1zLkOwOFc1KM7:TR?=	M1jXXnNCVkeHUh?=
SK-MEL-1	MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPISHlKSzVyPUGuN\|A3PzlizszN	NVrhR5lOW0GQR1XS
AU565	M3HNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\rUoFKSzVyPUGuN\|E5PjNizszN	MoLkV2FPT0WU
Saos-2	M{DhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfqTWM2OD1zLkOzNlA2KM7:TR?=	NUfHUlBRW0GQR1XS
A549	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFwM{m5O{DPxE1?	NXuzN4dGW0GQR1XS
BFTC-909	NFfDSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XGXmlEPTB;MT60N\|MxPSEQvF2=	NWLlOWJKW0GQR1XS
MDA-MB-415	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7mO4JKSzVyPUGuOFg3QTJizszN	M{LpSXNCVkeHUh?=
639-V	NETBbYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\LS2lEPTB;MT61NFI1PSEQvF2=	M4T1ZXNCVkeHUh?=
A704	MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPzTWM2OD1zLkWwO\|g2KM7:TR?=	NUHUcoFbW0GQR1XS
PANC-03-27	M3HDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4P5emlEPTB;MT61NVQxQCEQvF2=	NULrSXBTW0GQR1XS
SK-MEL-28	NH;kS\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonJTWM2OD1zLkW2NFg2KM7:TR?=	MUTTRW5ITVJ?
Ramos-2G6-4C10	NIDQcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnKzTWM2OD1zLk[wO\|Q3KM7:TR?=	M2e5ZnNCVkeHUh?=
HuP-T4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nCR2lEPTB;MT62NFc4QCEQvF2=	NXrPclBGW0GQR1XS
VA-ES-BJ	M1HnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXyy[5JPUUN3ME2xMlYyOjdizszN	MkO4V2FPT0WU
EFM-19	MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\pfFhKSzVyPUGuOlE5OSEQvF2=	MWfTRW5ITVJ?
G-401	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPaU\|lYUUN3ME2xMlYzOTZ2IN88US=>	MnPtV2FPT0WU
D-566MG	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHjTWM2OD1zLk[yOVMh\|ryP	MXvTRW5ITVJ?
JVM-3	NXHKdIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTFwNkS4O\|Uh\|ryP	MX\TRW5ITVJ?
TK10	Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofCTWM2OD1zLk[3NFg{KM7:TR?=	Ml;qV2FPT0WU
BT-20	NXzaPFZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\zR4hKSzVyPUGuOlg6ODJizszN	NEm4VpNUSU6JRWK=
EGI-1	NEjsS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknXTWM2OD1zLki0O\|AyKM7:TR?=	NY\zbohTW0GQR1XS
EW-16	NGXWR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnsXmxkUUN3ME2xMlg2OTh{IN88US=>	MXPTRW5ITVJ?
NCI-H2228	NVfpfIpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFwOEWyNFMh\|ryP	NW\GSGR4W0GQR1XS
BB49-HNC	NYK4cnpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;DTWM2OD1zLki4OlkzKM7:TR?=	NGj4NWRUSU6JRWK=
G-402	M2[xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTpNoMzUUN3ME2xMlg6Pzl5IN88US=>	NUj0dGtNW0GQR1XS
NCI-H526	Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV33ZY1kUUN3ME2xMlkyOzlizszN	NWCzR4JRW0GQR1XS
ME-180	NHrIWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHwTWM2OD1zLkmzOFc4KM7:TR?=	MlTYV2FPT0WU
PFSK-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\aO2lEPTB;MT65OFQ2QCEQvF2=	M1Hj[XNCVkeHUh?=
TYK-nu	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTFwOUW4NlMh\|ryP	MWHTRW5ITVJ?
HOS	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLidGJ[UUN3ME2xMlk4QTR6IN88US=>	Mn3hV2FPT0WU
T98G	NHzlWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTFwOUmwNFYh\|ryP	NEDXNHVUSU6JRWK=
SK-MES-1	NF7ze\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjFdpd[UUN3ME2yMlAyOzN{IN88US=>	NH;RV3ZUSU6JRWK=
SNB75	NIPSNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjvTWM2OD1{LkCxOVQyKM7:TR?=	MV7TRW5ITVJ?
LAMA-84	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnXTWM2OD1{LkCyOlg6KM7:TR?=	MVzTRW5ITVJ?
CAL-39	NGHufHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnETWM2OD1{LkCzNlgh\|ryP	NE\FcWtUSU6JRWK=
LOXIMVI	M{nCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LOcmlEPTB;Mj6wOFA5PCEQvF2=	M{HXOXNCVkeHUh?=
NH-12	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTJwMEW0NlQh\|ryP	NIDKfIVUSU6JRWK=
NCI-H1048	M4jXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTJwMUC1NkDPxE1?	NF;zdnlUSU6JRWK=
KS-1	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTEfpFkUUN3ME2yMlEyODBzIN88US=>	M2n3fXNCVkeHUh?=
NCI-N87	NVPmfnlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPTOIZKSzVyPUKuNVM{QDRizszN	NGrvVWNUSU6JRWK=
CHP-212	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrSTFRKSzVyPUKuNVg1PDJizszN	MYjTRW5ITVJ?
HCC1419	NFTPb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjUOmlKSzVyPUKuNlEyOTVizszN	NHThOIlUSU6JRWK=
ES1	NF7FTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjBR3g1UUN3ME2yMlIyOzJ4IN88US=>	MVXTRW5ITVJ?
NCI-H2030	NWrlUYdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnqNYpvUUN3ME2yMlI1OTJ\|IN88US=>	M{\lbXNCVkeHUh?=
EW-22	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmW5TWM2OD1{LkK1NFY4KM7:TR?=	M2LkR3NCVkeHUh?=
A431	NWDicng3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW[0N2dpUUN3ME2yMlI4OzV2IN88US=>	NFrZZopUSU6JRWK=
SF126	NH;XXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjEb2pSUUN3ME2yMlMxPjJ3IN88US=>	NHO0OFZUSU6JRWK=
SF295	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPjW4tKSzVyPUKuN\|E2OjRizszN	NIDOXGVUSU6JRWK=
D-502MG	NEDie5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJwM{K0OlEh\|ryP	M4WzWHNCVkeHUh?=
HCC2157	Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXwS212UUN3ME2yMlMzQTJ5IN88US=>	NH22N4VUSU6JRWK=
D-283MED	M2TTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTJwM{W5NlYh\|ryP	NGHFfJRUSU6JRWK=
SNU-423	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrQTWM2OD1{LkSwNVcyKM7:TR?=	MlWxV2FPT0WU
SK-LU-1	NYi1UJJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTJwNES1PFYh\|ryP	NH2weYJUSU6JRWK=
22RV1	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIf4cYJKSzVyPUKuOFU3OTdizszN	NUPuRoRHW0GQR1XS
SW1088	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkSwTWM2OD1{LkS5NlE{KM7:TR?=	NVnjZ\|Q5W0GQR1XS
HT-3	NEjiXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJwNEmyOVkh\|ryP	NHfN[W5USU6JRWK=
NCI-H1666	MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTsTWM2OD1{LkWxNVA1KM7:TR?=	NIjZOHFUSU6JRWK=
EM-2	NWGyN45oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnTSmxvUUN3ME2yMlUyOTZ7IN88US=>	M3TlNnNCVkeHUh?=
SNU-449	NWj2R3FmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4S4cWlEPTB;Mj61O\|AyPCEQvF2=	NHrLdndUSU6JRWK=
786-0	NH\nSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7nTWM2OD1{LkW5NlM5KM7:TR?=	Ml2xV2FPT0WU
SKG-IIIa	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIO2VI5KSzVyPUKuOlU6OzlizszN	NHz5W3VUSU6JRWK=
MEL-HO	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3j6dmlEPTB;Mj62O\|Y{PCEQvF2=	NXz4[mdGW0GQR1XS
LCLC-97TM1	NH;lZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYH0eHg1UUN3ME2yMlY6OjZ5IN88US=>	M2rqSHNCVkeHUh?=
MKN7	NFf2dllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGD1OYNKSzVyPUKuO\|A4PTRizszN	MojGV2FPT0WU
5637	M3;rb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWm1WFFIUUN3ME2yMlcyODN3IN88US=>	Mne1V2FPT0WU
HOP-92	NFTodZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;ORoxZUUN3ME2yMlc1PzF5IN88US=>	MkizV2FPT0WU
MDA-MB-157	M{nsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoH3TWM2OD1{LkiyNFI{KM7:TR?=	NHjVeplUSU6JRWK=
NB12	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjL[WdKSzVyPUKuPFQ6OTRizszN	MofHV2FPT0WU
DMS-273	M3jXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rTT2lEPTB;Mj64OlQ4KM7:TR?=	NUK0[pBTW0GQR1XS
HCC70	NVrtWYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\mT2lEPTB;Mj64OlU5QSEQvF2=	NWPXc5ZtW0GQR1XS
YKG-1	NI\4OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTNwMEO3PFch\|ryP	MmTkV2FPT0WU
NCI-H28	NF3tTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2j5XmlEPTB;Mz6wOVI6OSEQvF2=	M1nOU3NCVkeHUh?=
HN	MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7wVmFKSzVyPUOuNFY3OzZizszN	NYroNG9qW0GQR1XS
HT-1080	NVe3O5h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TMV2lEPTB;Mz6wPFYxPiEQvF2=	NGLRS3ZUSU6JRWK=
HPAF-II	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTNwMUCwOlgh\|ryP	NVPHWYEzW0GQR1XS
U-2-OS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnKwTWM2OD1\|LkGzO\|gzKM7:TR?=	MmHGV2FPT0WU
SNU-387	NWTKVo94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nFS2lEPTB;Mz6xOlM3PCEQvF2=	M2TxPHNCVkeHUh?=
Becker	NF;hWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTSNHZNUUN3ME2zMlE3QDB6IN88US=>	NEnjOVhUSU6JRWK=
BHY	NFvjOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXJPHFKSzVyPUOuNlU2PzFizszN	NIS4OFZUSU6JRWK=
HTC-C3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIKzPGhKSzVyPUOuNlk{PTJizszN	MYDTRW5ITVJ?
M14	NYLjXItJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTNwM{C2OlMh\|ryP	NIrSRWRUSU6JRWK=
COR-L23	M2HIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHGwb4pKSzVyPUOuN\|czPzlizszN	NXv4eIQzW0GQR1XS
C32	NV3PXllmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPCTWM2OD1\|LkSxOVA5KM7:TR?=	M3nLW3NCVkeHUh?=
Mewo	NV7UOYl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDITWM2OD1\|LkSyNVgzKM7:TR?=	NX3Y[ZZ6W0GQR1XS
TE-8	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTNwNEiyOVkh\|ryP	MlPUV2FPT0WU
RPMI-2650	M{\kRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXDdYNKSzVyPUOuOlA3OzdizszN	NFewUINUSU6JRWK=
AGS	NG\yfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jPcWlEPTB;Mz62NlQ3PCEQvF2=	MnnmV2FPT0WU
MZ2-MEL	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnJXIVKSzVyPUOuOlYyOzhizszN	NWnqXXNJW0GQR1XS
Calu-3	NYTmeHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PjeGlEPTB;Mz63NVI5PyEQvF2=	M1XvSHNCVkeHUh?=
SJSA-1	Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTNwN{GzNVUh\|ryP	NF;vPHRUSU6JRWK=
SW962	M3HuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\pfW9oUUN3ME2zMlczPjN4IN88US=>	NGfzeGRUSU6JRWK=
PC-14	NVP3cW5vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;KTWM2OD1\|LkezNlIzKM7:TR?=	MnXzV2FPT0WU
SW1573	MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzGTItKUUN3ME2zMlc2OzR6IN88US=>	MonJV2FPT0WU
769-P	NFLz[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XMcGlEPTB;Mz64Nlc1OyEQvF2=	MWPTRW5ITVJ?
KNS-62	M4Xzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonGTWM2OD1\|LkmyN\|M5KM7:TR?=	Mly5V2FPT0WU
NCI-H747	MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTRwMEW2N\|gh\|ryP	M1\zRnNCVkeHUh?=
LN-405	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rlcmlEPTB;ND6xOVczQCEQvF2=	NUCxdnpnW0GQR1XS
OVCAR-8	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13LfWlEPTB;ND6yNlU1OyEQvF2=	M1y5OnNCVkeHUh?=
DMS-114	NYC1b\|dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHSb3ZwUUN3ME20MlI{QDlzIN88US=>	NHzw[HNUSU6JRWK=
NCI-H2126	M{PoVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPVTWM2OD12LkK0OVU5KM7:TR?=	NVjXOWlzW0GQR1XS
TCCSUP	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrNelRnUUN3ME20MlI1Pzh6IN88US=>	MVPTRW5ITVJ?
SK-N-FI	M3L5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTTTWM2OD12LkK1N\|MzKM7:TR?=	NGHCNmZUSU6JRWK=
HCE-4	NGnLR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfjO\|RKSzVyPUSuNlcyQTdizszN	NYPBdXBNW0GQR1XS
DK-MG	NEXKUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[0[HlKSzVyPUSuN\|A{QSEQvF2=	Mnz2V2FPT0WU
RO82-W-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTRwM{K1PFQh\|ryP	M{e5SXNCVkeHUh?=
A2780	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlf2TWM2OD12LkO2OlgzKM7:TR?=	M1no[nNCVkeHUh?=
ETK-1	Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe0OmJuUUN3ME20MlM4ODV{IN88US=>	M2foW3NCVkeHUh?=
FADU	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTRwM{e0Olch\|ryP	NXjFU5dDW0GQR1XS
CAL-12T	NEjaTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzsTWM2OD12LkSxOFE{KM7:TR?=	NF7KfG1USU6JRWK=
647-V	M1XyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXmTWM2OD12LkS0NFIzKM7:TR?=	M1\YZXNCVkeHUh?=
TGBC1TKB	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnaV2NKSzVyPUSuOFUyOTNizszN	MmnWV2FPT0WU
LU-99A	M1;3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XBUWlEPTB;ND60OlA3KM7:TR?=	NFzFW4NUSU6JRWK=
CAL-33	MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jDOWlEPTB;ND61NlQ2PiEQvF2=	MkDLV2FPT0WU
LU-134-A	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fLVWlEPTB;ND61Nlc1PSEQvF2=	M3;jZXNCVkeHUh?=
NCI-H1355	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfzW4pKSzVyPUSuOVUyPDZizszN	MWfTRW5ITVJ?
RPMI-7951	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DLNmlEPTB;ND61O\|AxOiEQvF2=	M2XRVXNCVkeHUh?=
TE-1	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTBTWM2OD12Lk[2NVQ{KM7:TR?=	NIThcXRUSU6JRWK=
OE33	NVOzclNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml:2TWM2OD12LkewOVEyKM7:TR?=	NYT2O5B2W0GQR1XS
CAL-51	MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn:5TWM2OD12LkexNFgzKM7:TR?=	MVnTRW5ITVJ?
SW1783	NFOzfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLpWJpbUUN3ME20Mlc2OzB6IN88US=>	MXzTRW5ITVJ?
BT-474	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFG0fGJKSzVyPUSuO\|Y{QDRizszN	NHe5RmFUSU6JRWK=
KYSE-520	NFzQTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XUNWlEPTB;ND64O\|M6OiEQvF2=	M3rPT3NCVkeHUh?=
8-MG-BA	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTLSWNnUUN3ME20Mlg5PTV5IN88US=>	MVPTRW5ITVJ?
IA-LM	NE\1UJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDTTWM2OD12Lkm5OFM2KM7:TR?=	M4DkXHNCVkeHUh?=
SW954	NHTybW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTzSpJvUUN3ME20Mlk6PDR\|IN88US=>	M1LqZXNCVkeHUh?=
RPMI-8226	NX6zZpV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLlTohKSzVyPUWuNFU1PjFizszN	M4HNUHNCVkeHUh?=
MKN1	Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTVwMEe5Nlch\|ryP	NXfPTGc4W0GQR1XS
A375	NHq2N4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfRTWM2OD13LkC5NlU3KM7:TR?=	NF\NeXdUSU6JRWK=
8305C	M3G1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTVwMEm4PFch\|ryP	MVjTRW5ITVJ?
CAL-62	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLQTWM2OD13LkG4NlU6KM7:TR?=	MXnTRW5ITVJ?
NB10	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLHTWM2OD13LkKyO\|Q1KM7:TR?=	MWfTRW5ITVJ?
OC-314	M3nUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGq4fFdKSzVyPUWuN\|c1PDRizszN	NH7HO2RUSU6JRWK=
PSN1	NWrufWI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\v[GlEPTB;NT6zPFI5PiEQvF2=	MVHTRW5ITVJ?
GR-ST	NVzidWNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTVwM{izNlIh\|ryP	NFjHNIlUSU6JRWK=
P12-ICHIKAWA	NFf1bYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfheXlUUUN3ME21MlQxOSEQvF2=	NYXNRWJHW0GQR1XS
NCI-H1092	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTVwNEGxOFgh\|ryP	MlX3V2FPT0WU
SCC-4	M{X4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTVwNEGzOVUh\|ryP	MljLV2FPT0WU
TE-6	MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTVwNEG4NVYh\|ryP	NYfwRZF6W0GQR1XS
DOHH-2	NHvQSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrHTWM2OD13LkSyNlQ5KM7:TR?=	Moj3V2FPT0WU
SW684	M3PrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTVwNk[zPFUh\|ryP	M1zvcnNCVkeHUh?=
CP50-MEL-B	NFLzRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTVwNki2PFQh\|ryP	M3LzfXNCVkeHUh?=
UM-UC-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfOTWM2OD13LkeyNlMyKM7:TR?=	MoPXV2FPT0WU
LC-2-ad	NXzXN2JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDkTWM2OD13Lke4NlUyKM7:TR?=	NYHHR\|BnW0GQR1XS
PC-3	M3;KOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{m5PGlEPTB;NT65NVYyPSEQvF2=	M{\3OHNCVkeHUh?=
CAN	Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfXOHdKSzVyPUWuPVI5OiEQvF2=	M1WzTnNCVkeHUh?=
ESS-1	MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLtOHFHUUN3ME21Mlk4QDZ7IN88US=>	Mli4V2FPT0WU
ATN-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvqTWM2OD14LkC1OVY5KM7:TR?=	MWLTRW5ITVJ?
BxPC-3	NXfN[ZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTDTWM2OD14LkC4NlE6KM7:TR?=	MYTTRW5ITVJ?
KYSE-150	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4n6NWlEPTB;Nj6xNlQ4PiEQvF2=	NIHEe4dUSU6JRWK=
RPMI-8866	MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTZwMUmxOlMh\|ryP	MmTjV2FPT0WU
SW780	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTZwMkC0NkDPxE1?	MWHTRW5ITVJ?
A388	Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjPTWM2OD14LkKzNVE2KM7:TR?=	NW\YfGU5W0GQR1XS
NCI-H1437	NELGe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIi5[4hKSzVyPU[uNlQxPzNizszN	MUnTRW5ITVJ?
NCI-H1755	NXTPb2l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;rfVJKSzVyPU[uN\|Y3OTJizszN	NHfZS4hUSU6JRWK=
LS-123	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTM[od7UUN3ME22MlQxPTJzIN88US=>	MV7TRW5ITVJ?
CaR-1	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHuW2ZKSzVyPU[uOFY{PzNizszN	NWLVd\|k1W0GQR1XS
RT-112	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTZwNkCzN\|gh\|ryP	NG\1SnlUSU6JRWK=
CGT	NFTMPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTZwN{O2PFEh\|ryP	NWT2bYdnW0GQR1XS
SW626	NYjaZnVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3hR4tKSzVyPU[uO\|M6PDZizszN	NFq2UZFUSU6JRWK=
AsPC-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnVTWM2OD14Lke0OVA4KM7:TR?=	Mn:xV2FPT0WU
SBC-5	NGTOc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HrS2lEPTB;Nj65O\|I6PyEQvF2=	MlLrV2FPT0WU
SF539	NEfRcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn:xTWM2OD14Lkm5N\|M{KM7:TR?=	Ml3zV2FPT0WU
TI-73	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\tTWM2OD15LkC2Nlg2KM7:TR?=	NYPweYVpW0GQR1XS
MHH-ES-1	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPZTWM2OD15LkC3O\|YzKM7:TR?=	MmnwV2FPT0WU
KYSE-510	MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPVTWM2OD15LkC4OFMzKM7:TR?=	MUnTRW5ITVJ?
EW-1	NWLZNINST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTJTWM2OD15LkO2PVk3KM7:TR?=	NUf2N5hHW0GQR1XS
SK-OV-3	Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFS4UHZKSzVyPUeuN\|k1OzJizszN	M1zVRnNCVkeHUh?=
MC-IXC	M4ryWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXUTWM2OD15LkSxPVczKM7:TR?=	MVnTRW5ITVJ?
HSC-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrmTWM2OD15LkSyO\|A2KM7:TR?=	MnzsV2FPT0WU
NCI-H2342	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLCdplwUUN3ME23MlUyPDlizszN	NFrhWWpUSU6JRWK=
NCI-H1792	NUDFU5I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmqxTWM2OD15LkWxO\|EyKM7:TR?=	M4\KWnNCVkeHUh?=
HT-1376	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHRTWM2OD15Lki3O\|c5KM7:TR?=	NIXQb4tUSU6JRWK=
EW-13	NF[z[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4CzfWlEPTB;Nz64PVk4PyEQvF2=	NF;YSo5USU6JRWK=
no-11	M4TvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTdwOUCxO\|Qh\|ryP	NVXn[XE3W0GQR1XS
Daoy	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjPSYpKSzVyPUeuPVQ{OjFizszN	MUPTRW5ITVJ?
COLO-800	M4fZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXr[WtKSzVyPUiuNFQyPjJizszN	MUXTRW5ITVJ?
GB-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4C0[2lEPTB;OD6wOlU3PSEQvF2=	MX;TRW5ITVJ?
SJRH30	NHjUWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTYVW1FUUN3ME24MlE2QDd6IN88US=>	NVPJPWNiW0GQR1XS
NCI-H2291	NV;FfZROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRThwMkmxPFch\|ryP	MXzTRW5ITVJ?
J82	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TMfmlEPTB;OD6yPVQ6OSEQvF2=	MV7TRW5ITVJ?
NCI-H596	MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXaTWM2OD16LkOxOFU{KM7:TR?=	NIfyVIRUSU6JRWK=
RERF-LC-MS	MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRThwM{S4OVYh\|ryP	MoXGV2FPT0WU
RH-18	MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWi0NIlJUUN3ME24MlM2ODR4IN88US=>	NF;BU4dUSU6JRWK=
SW48	NWDsPJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnj4TWM2OD16LkW5OFU{KM7:TR?=	MkLGV2FPT0WU
RD	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRThwNUmzPVEh\|ryP	MWPTRW5ITVJ?
MS-1	NV;lNJFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjKd4NRUUN3ME24MlYyOzh5IN88US=>	NVKwb3VnW0GQR1XS
ES6	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkexTWM2OD16LkezNVE6KM7:TR?=	NVTGXZFwW0GQR1XS
TE-12	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRThwN{e1NFUh\|ryP	MkLZV2FPT0WU
DBTRG-05MG	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4f3eWlEPTB;OD65NVIyPyEQvF2=	MnLhV2FPT0WU
KINGS-1	M1TGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRThwOUK5N\|gh\|ryP	NYDoOHVnW0GQR1XS
HLE	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4D1[mlEPTB;OD65N\|c5PSEQvF2=	M17MbHNCVkeHUh?=
MHH-NB-11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTlwMEG4N\|kh\|ryP	NYHNcJB4W0GQR1XS
U-87-MG	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmH4TWM2OD17LkK0N\|IyKM7:TR?=	MmP1V2FPT0WU
MN-60	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfGTWM2OD17LkK0OVQzKM7:TR?=	MUjTRW5ITVJ?
SAS	NHm3[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXybHpKSzVyPUmuNlU2QDFizszN	M3;xcXNCVkeHUh?=
NCI-H446	NUfQbmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXhPFBKSzVyPUmuN\|YyKM7:TR?=	NVyx[GhRW0GQR1XS
C-33-A	NGfRfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3qwUGlEPTB;OT60N\|k5QCEQvF2=	M1HHRXNCVkeHUh?=
RXF393	NEXiXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTlwNEewNFIh\|ryP	Mo\YV2FPT0WU
CGTH-W-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPFcIZKSzVyPUmuOFk{QDRizszN	NFroSJNUSU6JRWK=
RCM-1	M{HsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\ub2lEPTB;OT62N\|gxOSEQvF2=	M{HSZ3NCVkeHUh?=
SN12C	NEfT[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmizTWM2OD17Lk[1N\|M5KM7:TR?=	M3PuWnNCVkeHUh?=
KLE	NFOwNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjm[VVnUUN3ME25MlcxODB7IN88US=>	NFfSPZRUSU6JRWK=
EFO-21	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2yTWM2OD17Lke3N\|gzKM7:TR?=	MmHjV2FPT0WU
KYSE-70	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvhTWM2OD17Lki4NFEyKM7:TR?=	M1jlcnNCVkeHUh?=
D-247MG	M37p[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[4TW1KSzVyPUGwMlA2PjhizszN	NHTkR4tUSU6JRWK=
MPP-89	M4XEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33C[2lEPTB;MUCuNFk1PiEQvF2=	MV;TRW5ITVJ?
RVH-421	NIOzcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFyLkG1NFUh\|ryP	NXL0TIlLW0GQR1XS
NCI-H460	NX7Bc4NmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXtb4JKSzVyPUGwMlI5ODZizszN	NITreYxUSU6JRWK=
NOMO-1	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzFTWM2OD1zMD6zOVMzKM7:TR?=	NYe2PGNNW0GQR1XS
DEL	NWnjeVAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vp[2lEPTB;MUCuN\|c6PCEQvF2=	MnzxV2FPT0WU
HT55	NITM[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnO2TWM2OD1zMD62NlA2KM7:TR?=	MYTTRW5ITVJ?
MC116	NXfTT3U4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTFyLk[2OVUh\|ryP	NUP2OpVbW0GQR1XS
BB30-HNC	NFvGTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrDU5dKSzVyPUGwMlY3QSEQvF2=	NGrvO5pUSU6JRWK=
DJM-1	NIPQdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHOSXpUUUN3ME2xNE43QTR7IN88US=>	MnfNV2FPT0WU
ZR-75-30	NVOx[Zc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTFyLkm0OFEh\|ryP	MXvTRW5ITVJ?
U-118-MG	M3POUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHrRYtKSzVyPUGwMlk5QTZizszN	MV\TRW5ITVJ?
MSTO-211H	MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLNcpVEUUN3ME2xNU4xPzF4IN88US=>	MnG0V2FPT0WU
SW837	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTFzLkC5OFkh\|ryP	MkXvV2FPT0WU
HuCCT1	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjaZWs6UUN3ME2xNU4yOjhzIN88US=>	NEXaZVlUSU6JRWK=
RCC10RGB	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjiTWM2OD1zMT6xN\|Uh\|ryP	M1\2b3NCVkeHUh?=
NMC-G1	M2TPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFzLkG0PVMh\|ryP	MnTLV2FPT0WU
NCI-H650	M330b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfR[oRKSzVyPUGxMlM4QTRizszN	MkjDV2FPT0WU
HEC-1	M1zjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLW[XFzUUN3ME2xNU41OzJ6IN88US=>	NVjKTWtTW0GQR1XS
DU-4475	NV3vVZp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LQOmlEPTB;MUGuO\|M6OyEQvF2=	M2jkRnNCVkeHUh?=
DSH1	NHe1Xm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFzLke2NFYh\|ryP	MUHTRW5ITVJ?
HCC1569	NFTs[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDKUJpKSzVyPUGxMlc3PzhizszN	Mnn5V2FPT0WU
HCC1187	M4izU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4L2VmlEPTB;MUGuPFU5QCEQvF2=	M4PlUHNCVkeHUh?=
EW-11	NVmwdIw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvKb4Q2UUN3ME2xNU46PDd2IN88US=>	M3O2e3NCVkeHUh?=
LB2518-MEL	NGmyW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPPOZlKSzVyPUGyMlA2QSEQvF2=	MkH5V2FPT0WU
KALS-1	NH7r[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH76WmZKSzVyPUGyMlg2PTNizszN	NHHKSZRUSU6JRWK=
8505C	NUTWc5NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XoUmlEPTB;MUKuPFg2KM7:TR?=	NEHwV4RUSU6JRWK=
SK-N-DZ	NXHKZndxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\WdmlEPTB;MUOuNFQ2OyEQvF2=	M2fpV3NCVkeHUh?=
CHP-134	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLJenpJUUN3ME2xN{4yOTV6IN88US=>	NIjYNG9USU6JRWK=
HCE-T	NXTHPJNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4KybGlEPTB;MUOuNlM3PCEQvF2=	NFq2TGpUSU6JRWK=
LB-831-BLC	MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTxe\|JrUUN3ME2xN{43OjR4IN88US=>	NUXQOXVZW0GQR1XS
OVCAR-4	MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDZTIRKSzVyPUGzMlY2OjRizszN	NE\wRWtUSU6JRWK=
SW756	NF;GPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTF\|LkeyOFYh\|ryP	M2XpUXNCVkeHUh?=
OCUB-M	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvKbHI3UUN3ME2xN{45OTV4IN88US=>	MYPTRW5ITVJ?
SW982	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDjZWJKSzVyPUGzMlgzPzZizszN	MV;TRW5ITVJ?
DB	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfZSWJFUUN3ME2xN{45Ozh2IN88US=>	Mlf2V2FPT0WU
H-EMC-SS	MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHITWM2OD1zMz65NVM6KM7:TR?=	M{HxenNCVkeHUh?=
VMRC-RCZ	MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjYTWM2OD1zND6wNFE2KM7:TR?=	MoTBV2FPT0WU
CAKI-1	M4K1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmSyTWM2OD1zND6wNVMzKM7:TR?=	MVnTRW5ITVJ?
GI-1	M2HKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXOWIxWUUN3ME2xOE4xPjV6IN88US=>	M324UnNCVkeHUh?=
Ca9-22	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTF2Lk[wOVQh\|ryP	MnjIV2FPT0WU
TE-5	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TxUGlEPTB;MUSuO\|IxQCEQvF2=	NGqw[lFUSU6JRWK=
EFO-27	M4i1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTF2Lke2NlIh\|ryP	NHL3cHRUSU6JRWK=
CAL-72	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\QUGlEPTB;MUSuO\|c5OyEQvF2=	MmfXV2FPT0WU
GP5d	NFLLdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTF3LkC0O\|Qh\|ryP	MkXsV2FPT0WU
CAS-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LIV2lEPTB;MUWuNFY3KM7:TR?=	MVLTRW5ITVJ?
A2058	NHm2PWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVS0Unc5UUN3ME2xOU42PjN6IN88US=>	Mo\tV2FPT0WU
PANC-08-13	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrNTWM2OD1zNT62PFU6KM7:TR?=	MV;TRW5ITVJ?
Detroit562	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfZTWM2OD1zNT65NVM6KM7:TR?=	MV7TRW5ITVJ?
PANC-10-05	NGCzeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWi4epZSUUN3ME2xOk4xQDJzIN88US=>	MYfTRW5ITVJ?
KOSC-2	M2nzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIToWGZKSzVyPUG2MlEyOjVizszN	M2\SR3NCVkeHUh?=
GT3TKB	Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTF4LkG5PFEh\|ryP	NGjDfIVUSU6JRWK=
KM-H2	NIfQR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTF4LkO2OFYh\|ryP	NIXaUpdUSU6JRWK=
LB771-HNC	M4i4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkK5TWM2OD1zNj60OFIzKM7:TR?=	NG\zfWVUSU6JRWK=
SF268	NEnxTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLtTWM2OD1zNj60OVIh\|ryP	NFnjZmFUSU6JRWK=
OE19	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7iRYFwUUN3ME2xOk42OjRizszN	MofSV2FPT0WU
MLMA	M1\5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF[2Z4RKSzVyPUG2MlU2PzFizszN	MWPTRW5ITVJ?
MDA-MB-231	MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rtbGlEPTB;MU[uO\|E{PiEQvF2=	Mln4V2FPT0WU
TGW	M{\1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDvRWdKSzVyPUG2MlgyODJizszN	NUXBcFkyW0GQR1XS
MDA-MB-453	M{\4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLBTWM2OD1zNz6wNFA{KM7:TR?=	NVvpWpU{W0GQR1XS
SNU-C2B	NHvJXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfEUYwyUUN3ME2xO{4xOjN5IN88US=>	Mn3pV2FPT0WU
A427	NXrZTGtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXXTWM2OD1zNz6yN\|M1KM7:TR?=	NGTNXohUSU6JRWK=
SK-MEL-2	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXy5fGZ{UUN3ME2xO{4{OjF\|IN88US=>	MnvRV2FPT0WU
KURAMOCHI	NH\6TG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3L5VmlEPTB;MUeuN\|g6PyEQvF2=	MVnTRW5ITVJ?
IST-MEL1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlf4TWM2OD1zNz65NVgzKM7:TR?=	MWPTRW5ITVJ?
NCI-H1793	NW\GSJBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvScVZKSzVyPUG4MlE2QDFizszN	MlywV2FPT0WU
HCC1395	NHPveVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGL2bmVKSzVyPUG4MlU3OTFizszN	NISzZoRUSU6JRWK=
NUGC-3	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LJTWlEPTB;MUiuOlU5PCEQvF2=	Ml7UV2FPT0WU
BB65-RCC	M1W0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTF6Lk[2PUDPxE1?	NGHUWZpUSU6JRWK=
RMG-I	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLuTWM2OD1zOD63N\|gzKM7:TR?=	NEP6UJRUSU6JRWK=
LS-513	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3pWZRuUUN3ME2xPE46OjJ6IN88US=>	MkTFV2FPT0WU
MFM-223	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYD6[\|RxUUN3ME2xPU4xPzF4IN88US=>	MVzTRW5ITVJ?
NCI-H727	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDnRmlmUUN3ME2xPU4{Ojl3IN88US=>	MYPTRW5ITVJ?
KP-4	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTF7Lki1N\|Eh\|ryP	NXLEfHNFW0GQR1XS
NB13	Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTF7Lki4N\|kh\|ryP	MVHTRW5ITVJ?
UACC-893	NYLHWGF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnkO41MUUN3ME2xPU46PzV5IN88US=>	NW\tc4I1W0GQR1XS
HT-1197	NGjLZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTJyLkK5OVgh\|ryP	MWPTRW5ITVJ?
NCI-H2029	M1jZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITDPIxKSzVyPUKwMlMzPjZizszN	NYTRNFdPW0GQR1XS
GI-ME-N	MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHje45KSzVyPUKwMlM{PzNizszN	M4r2fXNCVkeHUh?=
OVCAR-3	MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIm1VllKSzVyPUKwMlU5OjJizszN	NFTVdZJUSU6JRWK=
HD-MY-Z	M4DJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvYO5ZKSzVyPUKxMlM3QTZizszN	M1vZUHNCVkeHUh?=
NTERA-S-cl-D1	M2OwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PpdmlEPTB;MkGuOlczOiEQvF2=	M1rJOXNCVkeHUh?=
SCH	NYTYdYd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnaVINKSzVyPUKyMlQ6PiEQvF2=	NVy2VHk5W0GQR1XS
KARPAS-299	NVGwdJFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVe5UFg1UUN3ME2yN{4{QDh5IN88US=>	NFjNSJJUSU6JRWK=
NCI-H1650	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTJ\|LkmyOFEh\|ryP	MoO0V2FPT0WU
ACHN	NU\OdW9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTJ2LkS2OVYh\|ryP	NH\o[otUSU6JRWK=
M059J	NFXHRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPaTWM2OD1{ND61OlM1KM7:TR?=	NWrCeZdlW0GQR1XS
AM-38	M4WxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjYPZdbUUN3ME2yOU41QDFizszN	MX3TRW5ITVJ?
KG-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnX5TWM2OD1{NT61OFk1KM7:TR?=	Ml;KV2FPT0WU
COLO-824	NVzPeoJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\ERYlKSzVyPUK1MlU2QTlizszN	NH\1WW9USU6JRWK=
NCI-H1155	NHjTPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTJ3LkW4OFch\|ryP	NYX0[FR4W0GQR1XS
NCI-H441	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfyTWM2OD1{NT63OFY2KM7:TR?=	MWPTRW5ITVJ?
J-RT3-T3-5	M{GycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGj1dY5KSzVyPUK2MlMxOjdizszN	Mn7qV2FPT0WU
JEG-3	M3rEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVqxUVdTUUN3ME2yOk43QDB3IN88US=>	MWnTRW5ITVJ?
RKO	NGTWcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnGeYJoUUN3ME2yOk44PjN{IN88US=>	NWHvXnJrW0GQR1XS
CAL-85-1	MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoD6TWM2OD1{Nz6yNVE5KM7:TR?=	M{LxUHNCVkeHUh?=
CAL-120	NGq5Xo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDHRW5KSzVyPUK3MlY6OTRizszN	NIrteZZUSU6JRWK=
NCI-H2452	NWTmbFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnSTWM2OD1{Nz63O\|E3KM7:TR?=	MoXQV2FPT0WU
NCI-H1395	NFrWRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnjUYxNUUN3ME2yO{44QDN\|IN88US=>	MXvTRW5ITVJ?
KYSE-450	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXmTWM2OD1{Nz65PFYzKM7:TR?=	M2nQRXNCVkeHUh?=
S-117	NX7abowyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJ7LkO4OVch\|ryP	MXfTRW5ITVJ?
SW13	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HlfmlEPTB;MkmuPFUyQSEQvF2=	NETTR4dUSU6JRWK=
ES3	MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjQTWM2OD1\|MD6zO\|M{KM7:TR?=	Ml7VV2FPT0WU
HCT-116	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWT5bW04UUN3ME2zNE42PTV2IN88US=>	MVXTRW5ITVJ?
NCI-H1693	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDlfZpTUUN3ME2zNE42QTR{IN88US=>	NH7ENHBUSU6JRWK=
VM-CUB-1	M4fBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXlTWM2OD1\|MD62OFE{KM7:TR?=	NGHoS3VUSU6JRWK=
NCI-H2170	M3;LXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vsPWlEPTB;M{GuOVc5PCEQvF2=	NXvufIJqW0GQR1XS
ALL-PO	NX;SZVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zpfWlEPTB;M{GuPFQzQCEQvF2=	NYHxXWJ7W0GQR1XS
NCI-H661	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTN{LkC2NlMh\|ryP	NVyyXYxRW0GQR1XS
NCI-H2347	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTCcmpKSzVyPUOyMlQ5OzdizszN	MlnQV2FPT0WU
FTC-133	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7KTWM2OD1\|Mj63NFYh\|ryP	NFq2dGhUSU6JRWK=
COLO-829	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nubGlEPTB;M{OuN\|Q3PyEQvF2=	NWnnWZJuW0GQR1XS
GOTO	NFzVbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{WxfGlEPTB;M{OuOVI2QCEQvF2=	NWLl[oFuW0GQR1XS
YAPC	NHL0OpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\XTWM2OD1\|Mz64NVU6KM7:TR?=	NVLYdINIW0GQR1XS
LCLC-103H	NY\RSWp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIj1OHFKSzVyPUO0MlE3OjRizszN	M4TPbXNCVkeHUh?=
SiHa	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TUcmlEPTB;M{SuN\|gyPyEQvF2=	M1O5R3NCVkeHUh?=
LK-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmj1TWM2OD1\|ND61O\|A5KM7:TR?=	NWnQTpdbW0GQR1XS
KP-N-YS	M{K4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkj4TWM2OD1\|ND63NlAzKM7:TR?=	NF;jO\|NUSU6JRWK=
NCI-SNU-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7uXVZCUUN3ME2zOU4yPzlizszN	NXLiflZiW0GQR1XS
KNS-81-FD	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTN3Lk[2N{DPxE1?	MUXTRW5ITVJ?
SCC-9	NYrBNJl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHtOIhtUUN3ME2zOk44OTR4IN88US=>	MlTFV2FPT0WU
SH-4	M324b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTN4LkezJO69VQ>?	MUPTRW5ITVJ?
HCC-1954	NFLaNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XXcGlEPTB;M{euNlczQSEQvF2=	NXnJVoN4W0GQR1XS
BALL-1	M4GxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXhNHRQUUN3ME2zO{42OzF4IN88US=>	M{jMTnNCVkeHUh?=
BE-13	M4XaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnYO2NKSzVyPUO3MlcxOThizszN	NHvPSGRUSU6JRWK=
COLO-678	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzhVlJjUUN3ME2zO{46PDN5IN88US=>	MW\TRW5ITVJ?
SK-MEL-3	Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHITWM2OD1\|OD6yN\|k4KM7:TR?=	MYXTRW5ITVJ?
OAW-28	M4fIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkewTWM2OD1\|OD62N\|kh\|ryP	M4X2WnNCVkeHUh?=
CAMA-1	NVvINWVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTN6Lkm2PVEh\|ryP	MUXTRW5ITVJ?
C2BBe1	NI\kbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInHNoFKSzVyPUO5MlgyQCEQvF2=	MUjTRW5ITVJ?
A3-KAW	NX7X[4d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXmeZRyUUN3ME20NE4{PjZzIN88US=>	M1PoVnNCVkeHUh?=
SK-MEL-24	NGXpUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTRyLkW5N\|Eh\|ryP	NHvDOWdUSU6JRWK=
KYSE-140	MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PHOWlEPTB;NECuO\|E3PSEQvF2=	NEnkNoNUSU6JRWK=
MOLT-16	NV:xbFFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2CzVmlEPTB;NEGuNVU{PiEQvF2=	NFi3SW9USU6JRWK=
CFPAC-1	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTR{LkWyNVEh\|ryP	NHfoXZRUSU6JRWK=
NB14	NFWzdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIruUVhKSzVyPUSyMlcxOjdizszN	NWLaNFBDW0GQR1XS
COLO-792	NUD4WIw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPwTWM2OD12Mj64PVYyKM7:TR?=	NWfPZmdJW0GQR1XS
RH-1	NF[3OmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTJN5d1UUN3ME20N{41QDN4IN88US=>	MnrwV2FPT0WU
NCI-H522	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkWyTWM2OD12ND6zOVY5KM7:TR?=	NHfMUlBUSU6JRWK=
Ca-Ski	M3XiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknKTWM2OD12ND64NVE1KM7:TR?=	NEnSfW5USU6JRWK=
KGN	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTR6LkOwOlMh\|ryP	NYrWZ\|IyW0GQR1XS
UACC-62	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXpTWM2OD12OD60NFczKM7:TR?=	NYfZSVlCW0GQR1XS
NCI-H358	NFjOR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\sUXhKSzVyPUS5MlMxOThizszN	NHXofmtUSU6JRWK=
LS-411N	M4qzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTR7LkOxNVgh\|ryP	Ml\wV2FPT0WU
IST-MES1	NHnmdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjTO\|Y5UUN3ME20PU42PjJ3IN88US=>	M2fGNXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	+ Expand Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	+ Expand Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Formulation: Dissolved in 10% DMSO, 5% Tween 20, 85% water Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	RG7321

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT02092831	Completed	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01740336	Completed	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01437566	Completed	Breast Cancer	Genentech Inc.	October 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products4

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Dactolisib (BEZ235, NVP-BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 76 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 76 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)